Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
CA5-C82E9 | Cynomolgus | Biotinylated Cynomolgus CA125 / MUC16 Protein, His,Avitag™ (MALS verified) |
|
||
CA5-M52H6 | Mouse | Mouse CA125 / MUC16 Protein, His Tag (MALS verified) | |||
CA5-C52H8 | Cynomolgus | Cynomolgus CA125 / MUC16 Protein, His Tag (MALS verified) |
|
||
CA5-R52H3 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (12664-12920) Protein, His Tag (MALS verified) |
|
||
CA5-R52H6 | Rhesus macaque | Rhesus macaque CA125 / MUC16 (13647-14291) Protein, His Tag (MALS verified) |
|
||
CA5-H52H6 | Human | Human CA125 / MUC16 (13810-14451) Protein, His Tag (MALS verified) |
|
||
CA5-H82F8 | Human | Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™ |
|
||
CA5-H82F4 | Human | Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™ |
|
Biotinylated Mouse Mesothelin, His,Avitag (Cat. No. MSN-M82E7) immobilized on CM5 Chip can bind Mouse CA125 Protein, His Tag (Cat. No. CA5-M52H6) with an affinity constant of 16.4 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms | Details |
REGN-5668 | REGN-5668 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
Ubamatamab | REGN-4018 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
JCAR-020 | JCAR-020 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Solid tumours; Neoplasms | Details |
huAR9.6-IRDye800 | University Of Nebraska Medical Center | Details | |||
Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma | Details |
LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms | Details |
REGN-5668 | REGN-5668 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
Ubamatamab | REGN-4018 | Phase 2 Clinical | Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details | |
PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
JCAR-020 | JCAR-020 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Solid tumours; Neoplasms | Details |
huAR9.6-IRDye800 | University Of Nebraska Medical Center | Details |
This web search service is supported by Google Inc.